Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: A randomized controlled trial

Gastroenterology

Volumn 115, Issue 6, 1998, Pages 1340-1345

  Stack, W A ^a   Jenkins, D ^a   Vivet, P ^a   Hawkey, C J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOROPAFANT; MESALAZINE; PLACEBO; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHINITIS; THROMBOCYTE ACTIVATION; ULCERATIVE COLITIS;

EID: 0031762795     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(98)70011-3     Document Type: Article

References (37)

1. VW Yang Eicosanoids and inflammatory bowel disease Gastroenterol Clin North Am 25 1996 317 332
2. CJ Hawkey YM Mahida AB Hawthorne Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators Agents Actions 35 1992 22 26
3. SM Prescott GA Zimmerman TM McIntyre Platelet-activating factor J Biol Chem 265 1990 17381 17384
4. AC Rosen JL Wallace BJR Whittle Potent ulcerogenic actions of platelet-activating factor in the stomach Nature 319 1986 54 57
5. XM Sun W Hsueh Platelet activating factor produces shock, in vivo complement activation and tissue injury in mice J Clin Invest 147 1988 509 514
6. CA Musemeche M Caplan W Hsueh X Sun A Kelly Experimental necrotizing enterocolitis: the role of polymorphonuclear neutrophils J Pediatr Surg 26 1991 1047 1050
7. L Pons MT Droy-Lefaix L Bueno Leukotriene B for participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats Gastroenterology 102 1992 149 156
8. R Eliakim F Karmeli E Okan D Rachmilewitz Ketotifen effectively prevents mucosal damage in experimental colitis Gut 33 1992 1498 1503
9. JL Wallace Release of platelet activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of colonic colitis Can J Physiol Pharmacol 626 1988 422 425
10. C Pothoulakis F Karmeli CP Kelly R Eliakim MA Joshi CJ O'Kane I Castagliuolo JT LaMont D Rachmilewitz Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum Gastroenterology 105 1993 701 707
11. M Fonteles GG Fang MN Thielman PS Yotseff RL Guerrant Role of platelet activating factor in the inflammatory and secretory effects of Clostridium difficile toxin A J Lipid Mediat Cell Signal 11 1995 133 143
12. R Eliakim F Karmeli E Razin D Rachmilewitz Role of platelet factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine and prednisolone Gastroenterology 95 1988 1167 1172
13. L Ferraris F Karmeli R Eliakim J Klein C Fiocchi D Rachmilewitz Intestinal epithelial cells contribute to enhanced generation of platelet activating factor in ulcerative colitis Gut 34 1993 665 668
14. CB Appleyard K Hillier Biosynthesis of platelet activating factor in normal and inflamed human colon mucosa: evidence for the involvement of the pathway of platelet activating factor synthesis de novo in inflammatory bowel disease Clin Sci 88 1995 713 717
15. TD Wardle L Hall LA Turnberg Platelet activating factor: release from colonic mucosa in patients with ulcerative colitis and its effect on colonic secretion Gut 38 1996 355 361
16. E Thyssen J Turk A Bohrer WF Stenson Quantification of distinct molecular species of platelet activating factor in ulcerative colitis Lipids 31 1996 S255 S259
17. J Meenan TA Grool DW Hommes S Dijkhuizen FJ ten Kate M Wood M Whittaker GN Tytgat SJ van Deventer Lexipafant (BB-882), a platelet activating antagonist, ameliorates mucosal inflammation in ulcerative colitis Eur J Gastroenterol Hepatol 8 1996 569 583
18. W Hsueh F Gonzalez-Crussi JL Arroyave RC Anderson ML Lee WJ Houlihan Platelet activating factor induced ischaemic bowel necrosis: the effect of PAF antagonist Eur J Pharmacol 123 1986 79 83
19. A Pinto A Calignano N Mascolo G Autore F Capasso Castor oil increases intestinal formation of platelet activating factor and acid phosphatase release in the rat Br J Pharmacol 96 1989 872 874
20. A Pinto G Autore N Mascolo R Sorentino A Biondi AA Izzo F Capasso Time course of PAF formation by gastrointestinal tissue in rats after castor oil treatment J Pharm Pharmacol 44 1992 224 226
21. TW Kuijpers BC Hakkert MHL Hart D Roos Neutrophil migration across monolayers of cytokine pre-stimulated endothelial cells: a role for PAF and IL-8 J Cell Biol 117 1992 565 572
22. JM Herbert A Bernat G Valette A Gigo A Lale MC Laplace L Lespy P Savi JP Maffrand G Le Fur Biochemical and pharmacological activities of SR27417A, a highly potent, long acting platelet-activating factor receptor antagonist J Pharmacol Exp Ther 259 1991 44 51
23. JM Herbert G Valette A Bernat P Savi JP Maffrand G Le Fur SR27417A, a highly potent, selective and long acting antagonist of the PAF receptor Drugs Future 17 1992 1011 1018
24. 3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes J Lipid Mediat 7 1993 57 78
25. J Powell-Tuck J Bown JE Lennard-Jones A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis Scand J Gastroenterol 13 1978 833 837
26. SA Riley E Masiv MJ Goodman ME Herd S Dutt LA Turnberg Comparison of delayed release of 5-amino-salicylic acid (mesalazine) and of sulphasalazine in the treatment of mild to moderate ulcerative colitis Gut 29 1988 669 674
27. D Jenkins M Balsitis MF Dixon HM Gilmour NA Shepard A Theodossi GT Williams Guidelines for the initial biopsy of chronic inflammatory bowel disease. The British Society of Gastroenterology initiative J Clin Pathol 50 1997 93 105
28. AB Hawthorne RFA Logan CJ Hawkey PN Foster ATR Axon ET Swarbrick BB Scott JE Lennard-Jones Randomised controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20 22
29. SB Hanauer J Scharwtz M Robinson W Roufail S Arora J Cello M Safdi Mesalamine capsules as treatment for active ulcerative colitis: results of a controlled trial Am J Gastroenterol 88 1993 1188 1197
30. SB Hanauer Drug therapy. Inflammatory bowel disease N Engl J Med 334 1996 841 848
31. S Almer B Kald L Franzen M Strom C Tagesson Concentrations of platelet activating factor in rectal mucosa of patients with ulcerative colitis Eur J Surg 162 1996 306 391
32. WA Stack CJ Hawkey Specific mediator-directed therapy for gastrointestinal diseases Eur J Gastroenterol Hepatol 9 1997 1056 1061
33. CJ Hawkey LM Dube LV Rountree JF Lancaster European Zileuton Study Group for Ulcerative Colitis A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis Gastroenterology 112 1997 718 724
34. HM van Dulleman SJH van Deventer DW Hommes HA Bijl J Jansen GN Tytgat J Woody Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
35. WA Stack S Mann A Roy P Heath M Sopwith J Freeman GT Holmes RG Long A Forbes M Kamm CJ Hawkey A randomised control trial of CDP571, anti-TNFα antibody in Crohn's disease Lancet 349 1997 521 524
36. SR Targan SB Hanauer SJH van Deventer M Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease N Engl J Med 337 1997 1029 1035
37. DJ Evans PJ Barnes M Cluzel BJ O'Connor Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses Am J Respir Crit Care Med 156 1997 11 16